Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β.
Adult
Benzhydryl Compounds
/ pharmacology
Cross-Over Studies
Double-Blind Method
Female
Gastric Bypass
/ adverse effects
Glucose
/ metabolism
Glucosides
/ pharmacology
Humans
Hypoglycemia
/ drug therapy
Interleukin 1 Receptor Antagonist Protein
/ pharmacology
Interleukin-1beta
/ physiology
Male
Middle Aged
Postprandial Period
Proof of Concept Study
Sodium-Glucose Transporter 2 Inhibitors
/ pharmacology
IL-1
IL-1Ra
SGLT2
adipositas
bariatric surgery
hypoglycemia
inflammation
insulin
late dumping
metabolism
Journal
Cell metabolism
ISSN: 1932-7420
Titre abrégé: Cell Metab
Pays: United States
ID NLM: 101233170
Informations de publication
Date de publication:
07 04 2020
07 04 2020
Historique:
received:
06
09
2019
revised:
16
11
2019
accepted:
24
02
2020
pubmed:
21
3
2020
medline:
4
9
2021
entrez:
21
3
2020
Statut:
ppublish
Résumé
Postprandial hypoglycemia is a disabling complication of the treatment of obesity by gastric bypass surgery. So far, no therapy exists, and the underlying mechanisms remain unclear. Here, we hypothesized that glucose-induced IL-1β leads to an exaggerated insulin response in this condition. Therefore, we conducted a placebo-controlled, randomized, double-blind, crossover study with the SGLT2-inhibitor empagliflozin and the IL-1 receptor antagonist anakinra (clinicaltrials.govNCT03200782; n = 12). Both drugs reduced postprandial insulin release and prevented hypoglycemia (symptomatic events requiring rescue glucose: placebo = 7/12, empagliflozin = 2/12, and anakinra = 2/12, pval
Identifiants
pubmed: 32197070
pii: S1550-4131(20)30072-3
doi: 10.1016/j.cmet.2020.02.013
pii:
doi:
Substances chimiques
Benzhydryl Compounds
0
Glucosides
0
IL1B protein, human
0
Interleukin 1 Receptor Antagonist Protein
0
Interleukin-1beta
0
Sodium-Glucose Transporter 2 Inhibitors
0
empagliflozin
HDC1R2M35U
Glucose
IY9XDZ35W2
Banques de données
ClinicalTrials.gov
['NCT03200782']
Types de publication
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-709.e5Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests M.Y.D. is listed as an inventor on a patent submitted by University Hospital Basel covering the use of SGLT-2 inhibitors or IL-1R antagonists for reduction of hypoglycemia after bariatric surgery (EP19151525.3). All others declare no competing interests.